OHAMR Call for proposals 2026

General Information

• Type: Partner looking for project
• Organisation: Izmir Biomedicine and Genome Center
• Country: Turkey (TR)
• Career stage: Early Career Researcher (up to 8 years** since PhD).

Research area

• Scientific area(s) of the call:
  1. Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
• One Health Setting:

  H - Human Health

• Keywords:

  Antibodies; Protein engineering; Immunotherapy

• Brief description of your expertise / expertise you are looking for:

  I am an antibody engineer working on therapeutic or diagnostic antibody development, focusing on affinity, specificity, stability and manufacturability optimization. I work with both mammalian and microbial recombinant expression systems and analyze protein quality using various biochemical and biophysical assays. I am particularly interested in the use of antibodies to enhance or restore antimicrobial susceptibility and to target virulence factors. I seek collaboration with groups working on antimicrobial resistance infection models, antimicrobial screening, immunomodulation, delivery systems and clinical translation, where antibody-based tools could be combined to improve treatment outcome.

• Brief description of your project / the project you would like to join:

  I aim to contribute to a project focused on combination therapies that pair antibody treatments/diagnostics with antimicrobials to combat antimicrobial resistance. It can involve generating high-affinity antibodies against AMR-associated targets, such as virulence factors, membrane proteins, quorum sensing components, or biofilm-formers. Antibodies may be used to disrupt pathogen survival mechanisms, increase antimicrobial susceptibility, neutralize toxins, or prevent adhesion, allowing existing antibiotics to remain effective longer. I can support antibody discovery, engineering, production, purification and functional characterization, and contribute to in vitro binding/neutralization assays and mechanistic studies. I would be interested in joining consortia aiming to test antibodies, evaluate resistance reversal potential, or develop novel therapeutic formats (antibody fragments, fusion constructs, bispecific antibodies). I am open to both preclinical and translational research settings.

Sibel Kalyoncu Uzunlar

• Organisation: Izmir Biomedicine and Genome Center
• Position: Principle Investigator
• E-mail: sibel.kalyoncu@ibg.edu.tr
• Web: ibg.edu.tr/sibel-kalyoncu